POST Online Media Lite Edition



 

Three pharmaceutical companies to pay over $122m to resolve allegations that they paid kickbacks

Christian Fernsby |
The Department of Justice announced that three pharmaceutical companies, Jazz Pharmaceuticals, Lundbeck, and Alexion Pharmaceuticals, have agreed to pay a total of $122.6 million.

Article continues below




Those companies will to resolve allegations that they each violated the False Claims Act by illegally paying the Medicare or Civilian Health and Medical Program (ChampVA) copays for their own products, through purportedly independent foundations that the companies used as mere conduits.

When a Medicare beneficiary obtains a prescription drug covered by Medicare, the beneficiary may be required to make a partial payment, which may take the form of a copayment, coinsurance, or a deductible (collectively “copays”).

Similarly, under ChampVA, patients may be required to pay a copay for medications.

Congress included copay requirements in the Medicare program, in part, to serve as a check on health care costs, including the prices that pharmaceutical manufacturers can demand for their drugs.

The Anti-Kickback Statute prohibits a pharmaceutical company from offering or paying, directly or indirectly, any remuneration — which includes money or any other thing of value — to induce Medicare or ChampVA patients to purchase the company’s drugs.

This prohibition extends to the payment of patients’ copay obligations.

Jazz and Lundbeck each entered five-year corporate integrity agreements (CIAs) with OIG as part of their respective settlements.

The CIAs require the companies to implement measures, controls, and monitoring designed to promote independence from any patient assistance programs to which they donate.

In addition, the companies agreed to implement risk assessment programs and to obtain compliance-related certifications from company executives and Board members.

The government’s allegations in the three settlements being announced today are as follows:

Jazz sells Xyrem, a narcolepsy medication with Gamma Hydroxybutyrate (GHB)—a central nervous system depressant and controlled substance—as its main active ingredient.

The government alleged that, in 2011, Jazz asked a foundation to create a fund that would pay the copays of Xyrem Medicare patients and that the foundation agreed to establish a “Narcolepsy Fund,” to which Jazz became the sole donor.

The government alleged that Jazz knew that, although Xyrem accounted for a small share of the overall narcolepsy market, the fund almost exclusively used Jazz’s donations to pay copays for Xyrem and required non-Xyrem patients on competing products to obtain a denial letter from another assistance plan before helping them.

The government further alleged that, in conjunction with establishing this fund, Jazz made Medicare patients ineligible for Jazz’s free drug program and instead referred Xyrem Medicare patients to the foundation, enabling Jazz to generate revenue from Medicare and induce purchases of the drug, rather than continuing to provide these patients with free drugs.

Meanwhile, Jazz raised the price of Xyrem by over 150 percent from 2011 through the end of the relevant time period.

Jazz also sold Prialt, an injectable severe chronic pain medication.

The government alleged that Jazz asked the same foundation to create a fund ostensibly to assist patients with the co-pays of any severe chronic pain drugs, but which, in practice, almost exclusively paid Prialt Medicare copays.

Shortly after creating the fund, the foundation allegedly told Jazz that when severe chronic pain patients seeking assistance with other drugs contacted the foundation, it would refer them elsewhere.

The government alleged that Jazz was also aware that the fund did not appear on the foundation’s website, thereby minimizing the number of non-Prialt patients seeking assistance from the fund.

Jazz has agreed to pay $57 million to resolve the government’s allegations.

Lundbeck sells Xenazine, the only drug that was approved to treat chorea associated with Huntington’s disease until a generic version became available until 2015.

The government alleged that Lundbeck was the sole donor and made millions in payments to a fund at a foundation that ostensibly provided financial support only for patients with Huntington’s Disease.

However, Lundbeck allegedly referred Xenazine patients with many other conditions to this foundation, which then paid the Xenazine copays for these unapproved uses from its Huntington’s Disease fund.

The government further alleged that, in June 2014, after the foundation determined that its Huntington’s Disease fund would no longer pay the copays of patients taking Xenazine for non-Huntington’s disease uses, Lundbeck agreed to repurpose some of its prior donations to the Huntington’s Disease fund to a “general fund” at the foundation for the purpose of paying these patients’ Xenazine copays, and made subsequent “unrestricted” payments to the foundation with the understanding that the foundation would use these payments to pay Xenazine copays for these same patients.

Lundbeck allegedly asked the foundation whether there was a “risk” that this practice would be viewed as not compliant with the foundation’s HHS-OIG Advisory Opinion, and the foundation allegedly replied that “[t]hey don’t know what we use the general fund for.”

The government also alleged that, at the time it was engaged in the foregoing conduct, Lundbeck had a policy of not permitting Medicare or ChampVA patients to participate in its free drug program for Xenazine, which was open to other financially needy patients, even if those Medicare or ChampVA patients could not afford their copays for Xenazine.

Instead, in order to generate revenue from Medicare and ChampVA and to induce purchases of Xenazine, Lundbeck allegedly referred financially needy non-Huntington’s Disease Xenazine patients to the foundation, which resulted in claims to Medicare and ChampVA to cover the cost of the drug.

Lundbeck has agreed to pay $52.6 million to resolve the government’s allegations.

Alexion sells Soliris, which, from Jan. 1, 2010, through June 30, 2016, was indicated for certain uses to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

The cost of Soliris, based upon its list price and indicated dosing recommendation, can be approximately $500,000 per year.

The government alleged that Alexion made donations to a “Complement-Mediated Disease” (CMD) fund at a foundation to pay the Medicare copay obligations of patients taking Soliris and to induce those patients’ purchases of Soliris.

Alexion allegedly knew that the price it set for Soliris could pose a barrier to patients’ purchases of it.

In particular, the government alleged that Alexion approached the foundation in January 2010 to request that it create a fund to provide financial assistance to Soliris patients, including by paying patients’ Soliris Medicare copays and other medical expenses for Soliris patients.

Over the next several months, Alexion and the foundation allegedly discussed the coverage parameters for the fund, including Alexion’s desire that the foundation “not support a patient with any of these [CMD] diagnoses for other reasons tha[n] Soliris therapy.” After the fund opened, Alexion—the sole donor to the fund—allegedly understood that the foundation’s provision of financial assistance to a patient was contingent on the patient taking Soliris.

Alexion allegedly noted internally that it needed to be diligent in letting the foundation know if a patient had stopped taking Soliris so that Alexion’s donations would not be used on patients who were not starting or maintaining Soliris therapy.

Meanwhile, the government alleged that Alexion had a general practice of not permitting Medicare patients to participate in its free drug program, which was open to other financially needy patients, even if those Medicare patients could not afford their copays for Soliris.

Instead, in order to generate revenue from Medicare and induce purchases of Soliris, Alexion allegedly referred Medicare patients prescribed Soliris to the foundation, through the foundation’s “referral portal” software.

Allegedly, the “referral portal” reported information back to Alexion confirming those Soliris patients who were approved for copay or other financial assistance from the foundation, and detailed the foundation’s payments to them, which resulted in claims to Medicare to cover the cost of Soliris.

Alexion has agreed to pay $13 million to resolve the government’s allegations.

The government’s resolution of these matters illustrates the government’s emphasis on combating healthcare fraud.

One of the most powerful tools in this effort is the False Claims Act.


What to read next

AG Schneiderman obtains guilty plea from Mical Home Health Care
Competition Commission of India imposes penalty on pharma association and Lupin
Odebrecht and Braskem to pay $3.5bn in largest global foreign bribery case

U.S.: Alaska storm to bring significant coastal impacts, threat of flash flooding continues in southwest

 
Temperatures have begun plunging across the Northern Plains and Upper Midwest as a potent cold front pushes southward, bringing unseasonably frigid air behind it.
 
 

Latest

Governor Stitt calls out President Biden for ignoring border crisis
Delaware announces potassium iodide distribution event in Middletown
Governor Parson signs largest income tax cut in Missouri's history into law
Epiphone launches Joe Bonamassa 1962 ES-335 in Sixties Cherry

NEWS

Brazil seized vessel with 250kg of fertilizers in Foz do Iguaçu in state of Paraná

Brazil seized approximately 683kg of cocaine in Port of Santos
Estonia built 30 kilometers of bicycle and footpaths with support of European funds
Emergency call handlers in UK joining BT and Openreach strike today
RMT members working on buses in Somerset and Cornwall will strike
NetWalker affiliate sentenced to 20 years in prison
 

BUSINESS

ADB to provide up to $2.5b under flood relief support to Pakistan

Container throughput in Chinese ports rises in first eight months
Partners work on less noise and better fuel efficiency during airport approach
UK homes will lose double what they save in tax cuts
Union urges UK nurses to strike for first time in 106 years
66% of small U.S. business owners expect revenue increases over next year, 52% plan to expand
 

Trending Now

COVID-19: New clinical study realized with Belgian supplement shows promising results against COVID-19

U.S.: Alaska storm to bring significant coastal impacts, threat of flash flooding continues in southwest

Hyatt to enter exclusive collaboration agreement with Lindner Hotels

Governor Stitt calls out President Biden for ignoring border crisis


POLITICS

Novak: Russia insisting on access to Nord Stream investigation

Czech Republic, Qatar eye cooperation on economy, energy
Arab Parliament calls for full UN membership of Palestine
Germany criticizes friendly countries for charging astronomically high gas prices
Governor Justice: West Virginia ready for personal income tax cut
Governor Wolf: Rainy Day Fund reaches record high
 

Today We Recommend

Arab Parliament calls for full UN membership of Palestine


Highlights 

Aldi UK to recruit 3,000 ahead of festive season

New modern aluminum welding line in Alstom’s Wroclaw site will give jobs to 100 more people

UK homes will lose double what they save in tax cuts


COMPANIES

Rio Tinto partners with Voltalia for renewable solar power at Richards Bay Minerals

Hyatt to enter exclusive collaboration agreement with Lindner Hotels
Aldi UK to recruit 3,000 ahead of festive season
Crystal Lagoons brings beach life to Madrid
New modern aluminum welding line in Alstom’s Wroclaw site will give jobs to 100 more people
South Carolina: Boysen USA establishing operations in Spartanburg County
 

CAREERS

Farmers Group appoints Raul Vargas as president and CEO

Ara Partners hires Teresa O'Flynn as partner and co-lead of infrastructure strategy
Kimberly Nelson named president of Kemin Nutrisurance
Discovery Life Sciences appoints Suso J. Platero as chief scientific officer
Sandeep Johri joins LambdaTest board
Skyresponse appoints Mats Berthem as new CEO
 

ECONOMY

Canada's international trade drops in August

China's waterway freight volume up 4.9% in January-August
U.S. Services PMI at 56.7%
U.S. private sector employment increased by 208,000 jobs in September, annual pay up 7.8%
World Bank: Ukraine's economy to contract by 35% in 2022
Industrial producer prices up by 5.0% in euro area and by 4.9% in EU
 

EARNINGS

Helen of Troy Q2 2023 net sales revenue increased 9.7%

PwC announces record global revenues of $50 billion
AllianceBernstein's fund net assets 377,335,035
CarMax Q2 revenues $8.1 billion
Rite Aid Q2 net loss $331.3 million
NIKE Q1 2023 revenues $12.7 billion
 

OP-ED

Micromanaging is the worst enemy of efficiency and teamwork

Niger set to monetize massive gas reserves through Saharan natural gas pipeline
Putting the brakes on EV folly that choked the market
Oil discovery in Kavango Basin may mean huge benefits for Namibians
Cape Town and Dubai battle over Africa's energy future
Is America going to lose its superpower status?
 

AGRIFISH

Wisconsin: Vernon County deer farm confirmed with CWD

Farmers in all eight Connecticut counties now eligible for federal disaster assistance due to drought
Rancher sentenced for running $244 million “ghost cattle” scam
Exporters lose over $12,000 for every container of bananas contaminated with drugs in Ecuador
EFSA: Unprecedented number of summer avian influenza cases in Europe
43% of German forests privately owned
 

LEADERSHIP

Forget everything you know about hiring people

Cybervetting can have pronounced impact on workforce by broadening discrimination
Female managers pay fairer
Pitch quality of CEO voices rests entirely on gender
Employee turnover costs more than you think
51% of supply chain leaders increased number of network locations
 

CRIME

FINRA fines UBS Securities $2.5 million for regulation SHO violations and supervisory failures

Kim Kardashian to pay $1.26 million for unlawfully touting crypto security after SEC charges
SEC charges two Canadian programmers for GlobeNewswire with insider trading
Barclays agrees to $361 million settlement to resolve SEC charges relating to over-issuances of securities
Justice department announces total distribution of over $4 billion to victims of Madoff Ponzi Scheme
Bank of Ireland fined EUR100.5 million over tracker mortgage dispute
 

Magazine

TRAVEL

SureStay Hotel by Best Western Mt. Pleasant opens in Texas

Come to the astronomy capital of the world and meet the stars
All New Zealand fans of all things home and garden are welcome to Hamilton
Sanctuary Cap Cana opens in Dominican Republic
Skate with Olympic star Patrick Chan at Vancouver rinks
Annual Peanut Festival in Aubrey, Tx. is celebration of past and joy of present
 

SEA, LAND, AIR

Ford 2022 GT LM, 20 special supercars for collectors

2023 Ford F-Series Super Duty, built like never before
Caterham Super Sevens, true joy of ride
New Ford Mustang brings digital cockpit, new engines and style
Ram 1500 Limited Elite Edition joins lineup for 2023
2023 GMC Canyon AT4X, new midsize truck
 

DESIGN

Noritake tableware, to pass down to the new generation as an heirloom

Tecnografica wallcoverings from the land of ceramic
Poliform, kitchens for extraordinary homes
Luxury vinyl tiles, ideal combination of everything
LED lamps, long-lasting light for every space in your home
Clean and luxurious men's watches
 

GADGETS

Technics SL-1200, the legend keeps spinning

Leica S3, made in Germany for great pictures
Sennheiser HD 300 PROtect, pro headphones that protect your ears
HP Dragonfly Folio G3, very very good laptop for business users
Nokia PureBook Fold and PureBook Lite, flexibility and stylish design
Tascam 202MKVII, professional dual cassette deck
 

HEALTH

WHO probing Indian cough syrup after 66 children die in Gambia

COVID-19: New clinical study realized with Belgian supplement shows promising results against COVID-19
Lupin gets USFDA nod for HIV drug Darunavir
Roche launches its next-generation SARS-CoV-2 Rapid Antibody Test
FDA approves Taiho's LYTGOBI (futibatinib) tablets
New recommendations for terlipressin-containing medicines in treatment of hepatorenal syndrome
 

MEANTIME

Russian launches to space from U.S., first time in 20 years

Angola announces Angosat-2 satellite launch schedule
Chile announces proposal to create Desierto Florido National Park
UK to become first country to launch satellites into orbit from Europe
Laughing gas found in space could mean life
Three scientists share Nobel Prize in Physics for work in quantum mechanics